Basic Information
| LncRNA/CircRNA Name | ANRIL |
| Synonyms | CDKN2B-AS1, CDKN2B-AS, CDKN2BAS, NCRNA00089, PCAT12, p16AS |
| Region | GRCh38_9:21994778-22121097 |
| Ensemble | ENSG00000240498 |
| Refseq | NR_003529 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | breast cancer |
| ICD-0-3 | C50 |
| Methods | qRT-PCR etc. |
| Sample | breast tumor and separate blocks of normal tissue adjacent to tumor tissue,cell lines( MCF7 and MDA-MB-231 ) |
| Expression Pattern | up-regulated |
| Function Description | All tumors showed ANRIL expression in malignant cells, but amongst tumors ANRIL showed different subcellular locations with 56% of tumors with ANRIL only in the nucleus, 16% with ANRIL only in the cytoplasm and 28% with ANRIL in both the nucleus and cytoplasm. Cases with nuclear ANRIL were positively correlated with POSTN expression in malignant cells (? = 0.57, P = 0.0086), and no correlation was found between ANRIL and IL6 or CCL2. Reduced POSTN was also found using siRNA to ANRIL in MDA-MB-231 and MCF7 breast cancer cells. |
| Pubmed ID | 31572679 |
| Year | 2019 |
| Title | Long Non-coding RNA?ANRIL?in the Nucleus Associates With Periostin Expression in Breast Cancer |
External Links
| Links for ANRIL | GenBank HGNC NONCODE |
| Links for breast cancer | OMIM COSMIC |